KR102461176B1 - 빈혈 치료용 조성물 및 치료방법 - Google Patents

빈혈 치료용 조성물 및 치료방법 Download PDF

Info

Publication number
KR102461176B1
KR102461176B1 KR1020217011294A KR20217011294A KR102461176B1 KR 102461176 B1 KR102461176 B1 KR 102461176B1 KR 1020217011294 A KR1020217011294 A KR 1020217011294A KR 20217011294 A KR20217011294 A KR 20217011294A KR 102461176 B1 KR102461176 B1 KR 102461176B1
Authority
KR
South Korea
Prior art keywords
compound
delete delete
formula
daily dose
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217011294A
Other languages
English (en)
Korean (ko)
Other versions
KR20210043760A (ko
Inventor
로버트 쉘비츠
샤를로트 하트먼
악샤이 부흐
이사야 쉘비츠
존 야누스
조셉 가드너
Original Assignee
아케비아 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52022903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102461176(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아케비아 테라퓨틱스 인코포레이티드 filed Critical 아케비아 테라퓨틱스 인코포레이티드
Priority to KR1020227037446A priority Critical patent/KR102660040B1/ko
Publication of KR20210043760A publication Critical patent/KR20210043760A/ko
Application granted granted Critical
Publication of KR102461176B1 publication Critical patent/KR102461176B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217011294A 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법 Active KR102461176B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227037446A KR102660040B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201361834808P 2013-06-13 2013-06-13
US61/834,808 2013-06-13
US201361889478P 2013-10-10 2013-10-10
US61/889,478 2013-10-10
US201361898890P 2013-11-01 2013-11-01
US201361898885P 2013-11-01 2013-11-01
US61/898,890 2013-11-01
US61/898,885 2013-11-01
US201361912185P 2013-12-05 2013-12-05
US61/912,185 2013-12-05
KR1020167000558A KR102373245B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법
PCT/US2014/040889 WO2014200773A2 (en) 2013-06-13 2014-06-04 Compositions and methods for treating anemia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167000558A Division KR102373245B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037446A Division KR102660040B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법

Publications (2)

Publication Number Publication Date
KR20210043760A KR20210043760A (ko) 2021-04-21
KR102461176B1 true KR102461176B1 (ko) 2022-11-01

Family

ID=52022903

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217011294A Active KR102461176B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법
KR1020167000558A Active KR102373245B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법
KR1020227037446A Active KR102660040B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법
KR1020247012967A Pending KR20240055172A (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020167000558A Active KR102373245B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법
KR1020227037446A Active KR102660040B1 (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법
KR1020247012967A Pending KR20240055172A (ko) 2013-06-13 2014-06-04 빈혈 치료용 조성물 및 치료방법

Country Status (37)

Country Link
US (2) US11857543B2 (https=)
EP (2) EP4360706A3 (https=)
JP (6) JP2016521747A (https=)
KR (4) KR102461176B1 (https=)
CN (3) CN114404413A (https=)
AU (4) AU2014278543B2 (https=)
BR (1) BR112015031027A2 (https=)
CA (2) CA3151685A1 (https=)
CL (2) CL2015003602A1 (https=)
CY (2) CY1126699T1 (https=)
DK (1) DK3007695T3 (https=)
DO (1) DOP2015000297A (https=)
EC (1) ECSP20058592A (https=)
ES (1) ES2974273T3 (https=)
FI (2) FI3007695T3 (https=)
FR (1) FR24C1025I2 (https=)
HR (1) HRP20240319T1 (https=)
HU (2) HUE066123T2 (https=)
IL (3) IL243047B (https=)
LT (2) LT3007695T (https=)
MX (3) MX378150B (https=)
MY (1) MY204336A (https=)
NL (1) NL301278I2 (https=)
NO (1) NO2024025I1 (https=)
NZ (3) NZ753905A (https=)
PE (2) PE20201496A1 (https=)
PH (2) PH12015502738B1 (https=)
PL (1) PL3007695T3 (https=)
PT (1) PT3007695T (https=)
RS (1) RS65341B1 (https=)
RU (2) RU2019134558A (https=)
SG (2) SG11201509998WA (https=)
SI (1) SI3007695T1 (https=)
SM (1) SMT202400092T1 (https=)
TW (4) TWI791177B (https=)
WO (1) WO2014200773A2 (https=)
ZA (1) ZA201509024B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
NO2686520T3 (https=) 2011-06-06 2018-03-17
US10085661B2 (en) 2013-04-16 2018-10-02 Koninklijke Philips N.V. System and method for biventricular pacemaker pulse detection in surface ECG
JP2016521747A (ja) * 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) * 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN108401429A (zh) * 2016-12-06 2018-08-14 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基酰胺化合物及包含该化合物的组合物及其用途
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
JP2023501221A (ja) * 2019-10-31 2023-01-18 アケビア セラピューティクス インコーポレイテッド バダデュスタットを使用する治療方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
US20230190731A1 (en) * 2020-03-17 2023-06-22 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
EP4142721A1 (en) * 2020-04-29 2023-03-08 Bioage Labs, Inc. Hypoxia-inducible factor prolyl hydroxylase inhibitors for treating aging-related conditions
KR20230027157A (ko) 2020-06-19 2023-02-27 아케비아 테라퓨틱스 인코포레이티드 바다두스타트의 약물-약물 상호작용의 조절
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
EP4274575A1 (en) 2021-01-08 2023-11-15 Akebia Therapeutics Inc. Therapeutic methods using vadadustat
US20240148707A1 (en) * 2021-03-01 2024-05-09 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat
EP4308120A4 (en) 2021-03-19 2024-11-27 Zydus Lifesciences Limited TREATMENT OF SICKLE CELL ANEMIA

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
CA1261335A (en) 1984-08-29 1989-09-26 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Ethylenediamine monoamide derivatives
CN1023479C (zh) 1985-09-27 1994-01-12 弗·哈夫曼-拉罗切有限公司 乙二胺的单酰胺衍生物的制备方法
TW219933B (https=) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
ATE149485T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
CA2253282A1 (en) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1080075B1 (en) 1998-03-23 2004-08-11 Aventis Pharmaceuticals Inc. Piperididinyl and n-amidinopiperidinyl derivatives
GB9809213D0 (en) 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
DE69934582T2 (de) 1998-06-11 2007-10-04 Pharmacia & Upjohn Co. Llc, Kalamazoo Delavirdin tablettenformulierung
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
CA2434169C (en) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Spaced drug delivery system
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
DK2298301T3 (en) * 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
EP2258363A1 (en) 2002-05-17 2010-12-08 Celgene Corporation Compositions for treatment of cancers
WO2003101431A1 (en) * 2002-06-04 2003-12-11 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
RU2005108667A (ru) 2002-08-29 2005-08-27 Мерк энд Ко., Инк. (US) Производные n-биарилметиламиноциклоалканкарбоксамида
WO2004035812A2 (en) 2002-10-16 2004-04-29 Isis Innovation Limited Asparaginyl hydroxylases and modulators thereof
AU2003298611A1 (en) 2002-11-21 2004-06-18 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
ZA200610164B (en) 2004-05-28 2008-02-27 Fibrogen Inc HIF prolyl hydroxylase activity assay
TW200609218A (en) 2004-05-31 2006-03-16 Tanabe Seiyaku Co Bicyclic compounds
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
WO2006010920A1 (en) * 2004-07-30 2006-02-02 Isis Innovation Limited Soluble polypeptide
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
EP1960363B1 (en) 2005-12-09 2014-01-22 Amgen, Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
US20090023666A1 (en) 2006-01-09 2009-01-22 BTG plc Modulators of Hypoxia Inducible Factor-1 and Related Uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
KR100798730B1 (ko) * 2006-06-12 2008-01-29 신풍제약주식회사 록소프로펜 또는 잘토프로펜 함유 제어방출성 제제 및 그의제조방법
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
PL3357911T3 (pl) * 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
GB2444904B (en) 2006-12-05 2008-11-05 Michael Hilary Burke A Process For The Preparation of an Orally Administrable Unit Dose Tablet
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
CA2682929A1 (en) 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
JP2010524935A (ja) 2007-04-18 2010-07-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規１，８−ナフチリジン化合物
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
US8309544B2 (en) 2007-05-16 2012-11-13 Merck Sharp & Dohme Corp. Spiroindalones
CA2687306A1 (en) 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2186528B1 (en) 2007-08-06 2014-03-19 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
KR20100045480A (ko) 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
DE102008039959A1 (de) 2007-11-19 2009-05-20 Continental Teves Ag & Co. Ohg Druckregelventil
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
EA201000915A1 (ru) 2007-11-30 2011-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы пролилгидроксилазы
JP2011505367A (ja) 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
EP2307372B1 (en) 2008-07-23 2012-04-25 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
TW201006473A (en) 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
KR20110063537A (ko) 2008-09-15 2011-06-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 전이성 악성 흑색종 및 기타 암에 대한 항암 약물 및 이와 관련한 용도
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
US8137666B2 (en) 2008-11-22 2012-03-20 Academia Sinica Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses
WO2010114801A1 (en) 2009-03-31 2010-10-07 Ligand Pharmaceuticals Inc. Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
AU2010231615B2 (en) 2009-03-31 2014-05-15 Kissei Pharmaceutical Co., Ltd. Indolizine derivative and use thereof for medical purposes
EP3594213A1 (en) 2009-07-17 2020-01-15 Japan Tobacco Inc. Triazolopyridine compounds and action thereof as prolyl hydroxylase inhibitors and erythropoietin production inducers
RS54010B1 (sr) 2009-11-06 2015-10-30 Aerpio Therapeutics Inc. Inhibitori prolil hidroksilaze
US20140171465A1 (en) 2011-01-13 2014-06-19 Fibrogen, Inc. Methods For Increasing Reticulocyte Hemoglobin Content
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (https=) 2011-06-06 2018-03-17
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
CN104024227B8 (zh) 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
JP2016529257A (ja) 2013-08-16 2016-09-23 オハイオ ステート イノベーション ファウンデーション Ｄｎａメチル化を調節する組成物及び方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2016009331A (es) 2014-01-23 2016-10-26 Akebia Therapeutics Inc Composiciones y metodos para tratar enfermedades oculares.
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
MX2021003681A (es) 2018-10-03 2021-08-19 Akebia Therapeutics Inc Composiciones y metodos para el tratamiento de desordenes inflamatorios.
US11524939B2 (en) * 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Akebia closes $41 million series C (2013.6.4.) 1부.*
ClinicalTrials.gov Archive: NCT01235936 (2012.09.27.) 1부.*
Drug Dev Ind Pharm 35(6):671-677 (2009.6.) 1부.*
대한신장학회지 제25권 부록 제2호(2006) 1부.*

Also Published As

Publication number Publication date
PL3007695T3 (pl) 2024-07-01
US20160143891A1 (en) 2016-05-26
KR102373245B1 (ko) 2022-03-17
PE20160194A1 (es) 2016-04-20
SG10201910773VA (en) 2020-01-30
KR102660040B1 (ko) 2024-04-24
CY2024016I1 (el) 2025-05-09
CA2914662A1 (en) 2014-12-18
AU2024205219A1 (en) 2024-09-19
AU2014278543B2 (en) 2019-11-14
NZ714963A (en) 2020-07-31
AU2020200903A1 (en) 2020-02-27
EP3007695A2 (en) 2016-04-20
JP6612479B2 (ja) 2019-11-27
HUS2400023I1 (hu) 2024-07-28
EP3007695A4 (en) 2017-05-31
HRP20240319T1 (hr) 2024-05-24
JP2021191773A (ja) 2021-12-16
JP7672455B2 (ja) 2025-05-07
NL301278I2 (nl) 2024-08-01
TW201534302A (zh) 2015-09-16
AU2022200570B2 (en) 2024-05-02
CN114404413A (zh) 2022-04-29
EP3007695B1 (en) 2024-02-07
JP7328291B2 (ja) 2023-08-16
AU2022200570A1 (en) 2022-02-17
TWI791177B (zh) 2023-02-01
IL281058A (en) 2021-04-29
CL2015003602A1 (es) 2016-07-29
NO2024025I1 (no) 2024-05-29
JP2020033369A (ja) 2020-03-05
IL243047B (en) 2019-11-28
TW202446394A (zh) 2024-12-01
MX378150B (es) 2025-03-10
MX2022003510A (es) 2022-05-16
BR112015031027A2 (pt) 2017-08-29
RU2016100363A (ru) 2017-07-18
TWI712411B (zh) 2020-12-11
IL281058B1 (en) 2023-04-01
FIC20240023I1 (fi) 2024-06-25
FI3007695T3 (fi) 2024-03-13
ES2974273T3 (es) 2024-06-26
KR20210043760A (ko) 2021-04-21
NZ753904A (en) 2020-07-31
EP4360706A2 (en) 2024-05-01
AU2014278543A1 (en) 2016-01-07
IL270335B (en) 2021-03-25
ECSP20058592A (es) 2020-10-30
MX2015017229A (es) 2016-04-19
PH12015502738B1 (en) 2021-12-10
PE20201496A1 (es) 2020-12-29
RU2016100363A3 (https=) 2018-05-15
RU2705206C2 (ru) 2019-11-06
NZ753905A (en) 2020-07-31
AU2020200903B2 (en) 2021-11-04
CY2024016I2 (el) 2025-05-09
KR20240055172A (ko) 2024-04-26
KR20220151008A (ko) 2022-11-11
JP2025114609A (ja) 2025-08-05
FR24C1025I2 (fr) 2025-06-20
FR24C1025I1 (fr) 2024-07-26
US11857543B2 (en) 2024-01-02
PH12020551705A1 (en) 2021-11-15
TW202133843A (zh) 2021-09-16
SG11201509998WA (en) 2016-01-28
JP2019163293A (ja) 2019-09-26
HK1216844A1 (en) 2016-12-09
TW202339743A (zh) 2023-10-16
TW201922244A (zh) 2019-06-16
WO2014200773A3 (en) 2015-03-05
JP2016521747A (ja) 2016-07-25
CN105451739A (zh) 2016-03-30
CA2914662C (en) 2022-05-31
KR20160023773A (ko) 2016-03-03
PT3007695T (pt) 2024-03-07
PH12015502738A1 (en) 2016-03-07
CA3151685A1 (en) 2014-12-18
WO2014200773A2 (en) 2014-12-18
RU2019134558A (ru) 2020-02-20
LTPA2024521I1 (https=) 2024-07-10
JP2023145717A (ja) 2023-10-11
JP6937812B2 (ja) 2021-09-22
IL281058B2 (en) 2023-08-01
DK3007695T3 (da) 2024-03-18
SI3007695T1 (sl) 2024-04-30
TWI856464B (zh) 2024-09-21
US12569474B2 (en) 2026-03-10
CY1126699T1 (el) 2025-05-09
ZA201509024B (en) 2019-05-29
DOP2015000297A (es) 2016-03-15
CL2018002372A1 (es) 2018-12-28
MY204336A (en) 2024-08-23
MX391198B (es) 2025-03-21
SMT202400092T1 (it) 2024-05-14
US20240335434A1 (en) 2024-10-10
EP4360706A3 (en) 2024-07-10
RS65341B1 (sr) 2024-04-30
MX2020006963A (es) 2022-03-30
CN114404414A (zh) 2022-04-29
HUE066123T2 (hu) 2024-07-28
TWI650126B (zh) 2019-02-11
LT3007695T (lt) 2024-03-25

Similar Documents

Publication Publication Date Title
US12569474B2 (en) Compositions and methods for treating anemia
HK40109871A (en) Compositions and methods for treating anemia
HK1216844B (en) Compositions and methods for treating anemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G18-tex-PA0101

Protection beyond ip right term event data comment text: Claim Total Quantity : 4, Claim Number : 1, 5, 6 11, Period Limitation Text : 138, Comment Text : 17, 18

PE0702 Decision to register extension of term of patent right by permit, etc.

St.27 status event code: A-4-4-G10-G20-tex-PE0702

Protection beyond ip right term event data comment text: Claim Total Quantity : 4, Claim Number : 1, 5, 6 11, Period Limitation Text : 138, Comment Text : 17, 18

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)